LBT-6030 is an engineered Hybridtide® capable of activating two different signals (G-protein coupled receptors – GPCRs) that are directly involved in the treatment of diabetes. LBT-6030 is a dual agonist targeting the validated Glucagon-like peptide-1 (GLP-1) receptor in addition to Gastric inhibitory polypeptide receptor (GIP). Despite a crowded marketplace for GLP-1 agonists, LBT-6030 has a unique product profile.
LBT-6030 is a dual agonist as compared to existing GLP-1 agonists such as Exenatide or Liraglutide. In addition to being a dual agonist, LBT-6030 is currently being evaluated for oral delivery. The Hybridtide® scaffold provides robust and durable protease resistance in biological matrices such as the gastrointestinal tract and the bloodstream. LBT-6030 was optimized using the Longevity Biotech Oral Peptide Platform.
Finally, the Hybridtide® scaffold also provides for unique signalling capabilities we call Artisan Biology©. Artisan Biology provides a critical advantage over other peptide scaffolds (natural or otherwise) by enabling the ‘fine tuning’ of key biological signals that are involved in disease treatment. The ability to fine tune these signals can lead to a reduction in side effects amongst other benefits.
If you are interested in learning more about this program, please contact us.
LBT-6030 & Artisan Biology©
Hybridtides® provide unique and exquisite control over intracellular molecular biology signal transduction pathways. In addition to our oral delivery platform capabilities, Longevity Biotech is working to engineer specific product profile attributes as part of our development activities.
Specifically, Hybridtides® are able to distinguish between the cAMP and β Arrestin
pathways which lead to differentiated products and results.